Thilini H. Gamage

Thilini H. Gamage

Auto-generated profile, based on publicly available information

Thilini H. Gamage

Division of Orthopaedics, Section of Children’s Orthopaedics and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Cell Calcium
Verified
Journal Article
Open access
TGThilini H. Gamage
Thilini H. Gamage
GGGjermund Gunnes
Gjermund Gunnes
RLRobert Hugh Lee
Robert Hugh Lee
WLWilliam Edward Louch
William Edward Louch
AHAsbjørn Holmgren
Asbjørn Holmgren
EFEirik Frengen
Eirik Frengen
STIM1 and ORAI1 regulate store-operated Ca2+ entry (SOCE) in most cell types, and mutations in these proteins have deleterious and diverse effects. We established a mouse line expressing the STIM1 R304 W gain-of-function mutation causing Stormorken syndrome to explore effects on organ and cell physiology. While STIM1 R304 W was lethal in the homozygous state, surviving mice presented with reduced growth, skeletal muscle degeneration, and reduced exercise endurance. Variable STIM1 expression levels between tissues directly impacted cellular SOCE capacity. In contrast to patients with Stormorken syndrome, STIM1 was downregulated in fibroblasts from Stim1R304W/R304W mice, which maintained SOCE despite constitutive protein activity. In studies using foetal liver chimeras, STIM1 protein was undetectable in homozygous megakaryocytes and platelets, resulting in impaired platelet activation and absent SOCE. These data indicate that downregulation of STIM1 R304 W effectively opposes the gain-of-function phenotype associated with this mutation, and highlight the importance of STIM1 in skeletal muscle development and integrity.

7 February 2023 in Science Signaling
Verified
Journal Article
Closed access
TGThilini H. Gamage
Thilini H. Gamage
HGHerwig Grabmayr
Herwig Grabmayr
FHFerdinand Horvath
Ferdinand Horvath
MFMarc Fahrner
Marc Fahrner
DMDoriana Misceo
Doriana Misceo
EFEirik Frengen
Eirik Frengen
Stormorken syndrome is a multiorgan hereditary disease caused by dysfunction of the endoplasmic reticulum (ER) Ca 2+ sensor protein STIM1, which forms the Ca 2+ release–activated Ca 2+ (CRAC) channel together with the plasma membrane channel Orai1. ER Ca 2+ store depletion activates STIM1 by releasing the intramolecular “clamp” formed between the coiled coil 1 (CC1) and CC3 domains of the protein, enabling the C terminus to extend and interact with Orai1. The most frequently occurring mutation in patients with Stormorken syndrome is R304W, which destabilizes and extends the STIM1 C terminus independently of ER Ca 2+ store depletion, causing constitutive binding to Orai1 and CRAC channel activation. We found that in cis deletion of one amino acid residue, Glu 296 (which we called E296del) reversed the pathological effects of R304W. Homozygous Stim1 E296del+R304W mice were viable and phenotypically indistinguishable from wild-type mice. NMR spectroscopy, molecular dynamics simulations, and cellular experiments revealed that although the R304W mutation prevented CC1 from interacting with CC3, the additional deletion of Glu 296 opposed this effect by enabling CC1-CC3 binding and restoring the CC domain interactions within STIM1 that are critical for proper CRAC channel function. Our results provide insight into the activation mechanism of STIM1 by clarifying the molecular basis of mutation-elicited protein dysfunction and pathophysiology.

21 April 2026 in Journal of Children's Orthopaedics
Verified
Journal Article
Open access
TGThilini H. Gamage
Thilini H. Gamage
SCSílvia Coutinho
Sílvia Coutinho
Alberto LeardiniAlberto Leardini
Alberto Leardini
Ines AlvesInes Alves
Ines Alves
NGNadine Großmann
Nadine Großmann
JHJoachim Horn
Joachim Horn
Purpose: Clinical management of rare bone diseases (RBDs) is challenged by low prevalence, delayed diagnosis, and complex multidisciplinary needs. This survey aimed to map current clinical practices in RBDs, identify unmet needs, and generate foundational data to guide the development of minimum standards for patient assessment. Methods: An anonymous online survey was distributed to members of the European Paediatric Orthopaedic Society (EPOS) and the European Reference Network on Rare Bone Diseases (ERN BOND) in September 2025. Questions addressed diagnostic work-up, interdisciplinary care, transition practices, and future perspectives. Quantitative data were analysed descriptively, and free-text responses thematically. Results: A total of 119 respondents (35 countries), mostly orthopaedic surgeons (74%), completed the survey. Almost all (118/119) provided direct care, and 63% had >10 years’ experience treating RBDs. Over 80% routinely used anthropometric, posture, and alignment measures, whereas the use of advanced tools varied. Interdisciplinary care is widely applied at varying frequencies, with a high consideration for shared decision-making and quality of life. Most lacked registry access (>80%) and formal transition protocols (~70%). Respondents prioritised clinical frameworks over technological advances and anticipated increasing future relevance for technological innovations. Conclusions: This survey highlights considerable variability in clinical decision-making for RBDs. The findings underscore the importance and need of standardised interdisciplinary care, registry data, and structured protocols and frameworks. Study Significance: This is the first systematic survey of clinical practice and decision-making process in RBD care among EPOS and ERN BOND members. The findings may guide future recommendations and standards, supporting more harmonised care for individuals with RBDs, especially ultra-rare conditions.